Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 5. Click on ID to see further detail.
IDOV_5440 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineTohuku university Japan | Origin of cell lineHuman pancreatic cancer cell line | Cell linePSN1 | Concentration of cell lineNA | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viable after day 2 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27561180 |
IDOV_5441 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineTohuku university Japan | Origin of cell lineHuman pancreatic cancer cell line | Cell linePSN1 | Concentration of cell lineNA | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viable after day 4 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27561180 |
IDOV_5442 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineTohuku university Japan | Origin of cell lineHuman pancreatic cancer cell line | Cell linePSN1 | Concentration of cell lineNA | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viable after day 6 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27561180 |
IDOV_5443 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineTohuku university Japan | Origin of cell lineHuman pancreatic cancer cell line | Cell linePSN1 | Concentration of cell lineNA | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result90% cell viable after day 8 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27561180 |
IDOV_5444 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineTohuku university Japan | Origin of cell lineHuman pancreatic cancer cell line | Cell linePSN1 | Concentration of cell lineNA | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viable after day 10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27561180 |